INBX Inhibrx: ערך חשבונאי למניה

Inhibrx Biosciences (INBX) develops anti-tumor agents based on clinical test results, which carry more weight than macroeconomic factors. The business model is recession-proof, as the demand for treatment remains stable. Automated laboratories have been implemented to accelerate molecule discovery, and the current metric stands at -3.61. This chart of the company's price action clearly demonstrates the market quotes for this asset.

The metric is calculated as the ratio of equity minus intangible assets to the number of shares outstanding, determining the intrinsic value of an investor's stake. Given the capital-intensive nature of R&D, the book value per share for Inhibrx Biosciences (INBX) serves as an indicator of the company's financial stability in the face of FDA regulatory risks and the costs associated with patenting molecules.